Alto Neuroscience (NYSE:ANRO) Given New $38.00 Price Target at Robert W. Baird

Alto Neuroscience (NYSE:ANRO) had its price objective lowered by Robert W. Baird from $41.00 to $38.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Robert W. Baird’s target price would indicate a potential upside of 67.34% from the stock’s previous close.

A number of other brokerages also recently weighed in on ANRO. Jefferies Financial Group reissued a “buy” rating and issued a $35.00 price target on shares of Alto Neuroscience in a report on Monday, March 16th. BTIG Research lifted their price objective on shares of Alto Neuroscience from $27.00 to $28.00 and gave the stock a “buy” rating in a research report on Tuesday, February 17th. Wall Street Zen downgraded shares of Alto Neuroscience from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Chardan Capital restated a “buy” rating and set a $30.00 price target on shares of Alto Neuroscience in a research note on Thursday. Finally, HC Wainwright reiterated a “buy” rating and issued a $50.00 price objective on shares of Alto Neuroscience in a research note on Thursday. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $35.14.

Alto Neuroscience Stock Performance

Shares of ANRO traded down $0.70 on Thursday, reaching $22.71. 432,451 shares of the company’s stock traded hands, compared to its average volume of 251,591. The stock’s 50 day simple moving average is $19.09 and its two-hundred day simple moving average is $14.63. The stock has a market cap of $725.43 million, a PE ratio of -10.37 and a beta of 2.52. Alto Neuroscience has a 52-week low of $1.60 and a 52-week high of $25.17. The company has a current ratio of 15.69, a quick ratio of 15.69 and a debt-to-equity ratio of 0.12.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings data on Monday, March 16th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.11. On average, analysts forecast that Alto Neuroscience will post -2.54 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Alto Neuroscience

A number of large investors have recently made changes to their positions in the stock. Commodore Capital LP bought a new stake in shares of Alto Neuroscience during the fourth quarter valued at about $32,453,000. Artia Global Partners LP purchased a new stake in shares of Alto Neuroscience during the 4th quarter worth approximately $520,000. 683 Capital Management LLC purchased a new position in Alto Neuroscience during the 4th quarter valued at $1,153,000. Spruce Street Capital LP bought a new stake in Alto Neuroscience during the 4th quarter valued at $3,967,000. Finally, AdvisorShares Investments LLC purchased a new stake in shares of Alto Neuroscience during the fourth quarter valued at about $785,000.

Key Alto Neuroscience News

Here are the key news stories impacting Alto Neuroscience this week:

• Positive Sentiment: HC Wainwright reaffirmed its “buy” rating and set a $50.00 price target, signaling continued bullish conviction from at least one sell?side shop. Article Title
• Positive Sentiment: JonesTrading kept a “buy” rating despite cutting its price target from $49 to $44, indicating analysts still see meaningful upside to the current price. Article Title
• Positive Sentiment: Chardan Capital reaffirmed a “buy” rating with a $30 price target, providing additional buy?side support amid near?term volatility. Article Title
• Neutral Sentiment: Alto announced it is shifting focus toward ALTO?207 after the ALTO?101 topline results, which could reallocate resources and change timelines — a strategic pivot that reduces near?term clarity but may preserve longer?term pipeline value. Article Title
• Neutral Sentiment: The company’s official press release detailed the topline results and pipeline update; investors will watch follow?up data, protocol details and management’s development/prioritization plans for valuation impact. Business Wire Release
• Negative Sentiment: Topline Phase 2 results: ALTO?101 failed to achieve statistical significance on the trial’s primary endpoint — the principal catalyst for the stock decline as it raises questions about the program’s near?term commercial prospects. Investing.com Article
• Negative Sentiment: Coverage and headlines (e.g., MSN) are highlighting the failed schizophrenia study, increasing negative investor sentiment and trading activity. MSN Article
• Negative Sentiment: Wedbush lowered its price target to $21 (from $22) and moved to a “neutral” rating, reflecting reduced confidence and adding sell?side pressure. Article Title

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.